Quantitative 18F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer

Wenchao Ma; Minshu Wang; Xiaofeng Li; Hui Huang; Yanjia Zhu; Xiuyu Song; Dong Dai; Wengui Xu

doi:10.3892/ol.2018.9166

Quantitative ¹⁸F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer

Oncol Lett. 2018 Oct;16(4):4129-4136. doi: 10.3892/ol.2018.9166. Epub 2018 Jul 18.

Authors

Wenchao Ma^{1

2

3}, Minshu Wang^{1

2

3}, Xiaofeng Li^{1

2

3}, Hui Huang^{1

2

3}, Yanjia Zhu^{1

2

3}, Xiuyu Song^{1

2

3}, Dong Dai^{1

2

3}, Wengui Xu^{1

2

3}

Affiliations

¹ Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
² National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.
³ Tianjin Clinical Research Center for Cancer, Hexi, Tianjin 300060, P.R. China.

Abstract

The aim of the present study was to investigate the prognostic value of quantitative [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) parameters for patients with non-small cell lung cancer (NSCLC). The present study conducted a retrospective review of the medical records of 203 patients with NSCLC, of which 193 patients underwent baseline ¹⁸F-FDG PET/CT prior to initial therapy. Multivariate analyses using Cox's proportional hazards regression were performed for the assessment of the association between initial PET/CT measurements and overall survival (OS). The multivariate models were adjusted for sex, age, smoking status, disease stage, standardized uptake value (SUV), standardized uptake value corrected for lean body mass (SUL), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and standard deviation of SUV (SD). Kaplan-Meier (K-M) estimator curves were constructed following the formation of three approximately equal-sized groups using tertiles for each PET/CT measurement (n=65, 64 and 64). OS curves were plotted using K-M estimator curves. Results demonstrated significant associations between OS and MTV_{PET volume computerized assisted reporting (PETVCAR)}, MTV2.5, MTV25%, MTV42% and TLG_PETVCAR; however, no significant associations were identified between OS and MTV50%, MTV75%, TLG2.5, all SUV and SUL. Subgroup analyses according to pathology demonstrated that there were statistically significant associations between OS and stage (P<0.001), MTV50% (P=0.002) and MTV42% (P=0.004) in the adenocarcinoma group, and SUL_mean (P=0.010), MTV25% (P=0.005) and MTV42% (P=0.001) in the squamous cell carcinoma group; however, no significant differences were identified between any other group. Furthermore, there was a significant association between OS and MTV42% (P=0.02) and MTV50% (P=0.04) in the early-stage group; however, no significant differences were identified in the advanced-stage group. K-M estimator curve analyses demonstrated that the pathology (P=0.01), stage (P<0.001) and all PET metabolic parameters with the exception of SD were significantly associated with OS (P<0.05). No significant associations were demonstrated between SD and OS. In conclusion, ¹⁸F-FDG PET/CT MTV_PETVCAR, MTV2.5, MTV25%, MTV42% and TLG_PETVCAR exhibit prognostic values with regard to OS. Overall, selection of appropriate metabolic parameters may predict NSCLC prognosis.

Keywords: [18F]fluorodeoxyglucose; lung cancer; positron emission tomography/computed tomography; quantitative analysis; survival analysis.